Eli Lilly and Company (NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) approved a label expansion for Zepbound® (tirzepatide) to include the four-dose single-patient use ...
Interval colorectal cancers (CRCs) were lower when patients' endoscopists had a better sessile serrated lesion detection rate on screening colonoscopies, a large retrospective cohort study showed. ( ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results